Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAY736 and CFZ533 in Systemic Lupus Erythematosus
CTR20191864Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ianalumab, iscalimab in systemic lupus erythematosus (SLE), sponsored by Novartis. Started Nov 2019; status: completed.
02
Drugs
ianalumabiscalimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20191864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191864.